Agilent (A) AI Stock Analysis

• Market Cap: $38.85B
• Dividend Yield: 0.72%
• Average Volume (3M): 2.16M
• Price to Earnings (P/E): 30.0
• Beta (1Y): 0.95
• Revenue Growth: 6.73%
• EPS Growth: 3.34%
• Country: US
• Employees: 17,900
• Sector: Technology
• Sector Strength: 88
• Industry: Medical - Diagnostics & Research
• EPS (TTM): 1.59
• Shares Outstanding: 283,054,380
• 10 Day Avg. Volume: 2,397,823
• 30 Day Avg. Volume: 2,157,653
• PEG Ratio: 9.41
• Price to Book (P/B): 6.14
• Price to Sales (P/S): 5.96
• P/FCF Ratio: 35.95
• Enterprise Value/Market Cap: 1.11
• Enterprise Value/Revenue: 6.19
• Enterprise Value/Gross Profit: 11.80
• Enterprise Value/Ebitda: 23.43
• 1Y Price Target: $168.08
• Price Target Upside: 22.47% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 13
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 73 Outperform
• Price Target: $159.00 ▲(15.86% Upside)

Agilent's strong financial performance and positive earnings call guidance are key strengths, supporting a solid overall score. However, technical indicators suggest short-term caution, and the high valuation limits upside potential. Challenges in specific markets and increased tax rates also pose risks.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective product strategies, supporting long-term business expansion.

Innovative Product Launches

Successful new product launches enhance competitive positioning and drive future revenue streams, reinforcing Agilent's market leadership.

Operational Efficiency

Operational efficiencies lead to improved margins, enhancing profitability and providing a buffer against market volatility.

Negative Factors

Decline in Chinese Market

A decline in the Chinese market could hinder growth prospects in a key region, impacting overall revenue potential.

Challenges in Academia and Government Sectors

Reduced spending in academia and government sectors may limit growth opportunities in these segments, affecting long-term diversification.

Increased Tax Rate Impact

Higher tax rates reduce net income, potentially impacting reinvestment capabilities and shareholder returns over the long term.

Agilent Business Overview & Revenue Model

Company Description

Agilent Technologies, Inc. is a global leader in life sciences, diagnostics, and applied chemical markets. The company provides instruments, software, services, and consumables for laboratory workflows across various sectors, including pharmaceuticals, biotechnology, environmental testing, and food safety. Agilent's core products include analytical instruments, such as gas and liquid chromatography systems, mass spectrometry systems, and various laboratory informatics solutions, enabling customers to enhance their research and development processes.

How the Company Makes Money

Agilent generates revenue through a diversified business model primarily focused on three key segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The majority of its income comes from the sale of instruments and consumables, with recurring revenue also derived from services, support, and software subscriptions. Additionally, Agilent benefits from strategic partnerships and collaborations with research institutions and other companies, which enhance its product offerings and expand its market reach. The company's continuous investment in innovation and development of new technologies further contributes to its competitive edge and revenue growth.

Agilent Financial Statement Overview

Summary

Agilent demonstrates strong profitability with healthy margins and stable revenue growth. The balance sheet shows moderate leverage and a solid equity position, although the decline in ROE and free cash flow is a concern.

Income Statement

Agilent demonstrates strong profitability with a consistent gross profit margin above 50% and a net profit margin improving to 23.32% in the latest year. Revenue growth has been modest at 2.36%, indicating stable but slow expansion. EBIT and EBITDA margins are healthy, reflecting efficient operations.

Balance Sheet

The company maintains a reasonable debt-to-equity ratio of 0.50, indicating moderate leverage. Return on equity has decreased to 6.44%, suggesting a decline in profitability relative to equity. The equity ratio remains stable, reflecting a solid financial position.

Cash Flow

Free cash flow has decreased by 17.83%, which is a concern. However, the operating cash flow to net income ratio is strong at 0.66, indicating good cash generation relative to earnings. The free cash flow to net income ratio is also healthy at 0.74.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.95B	6.51B	6.83B	6.85B	6.32B
Gross Profit	3.64B	3.54B	3.46B	3.72B	3.41B
EBITDA	1.83B	1.87B	1.70B	1.91B	1.76B
Net Income	1.30B	1.29B	1.24B	1.25B	1.21B
Balance Sheet
Total Assets	12.73B	11.85B	10.76B	10.53B	10.71B
Cash, Cash Equivalents and Short-Term Investments	1.79B	1.33B	1.59B	1.05B	1.57B
Total Debt	3.35B	3.57B	2.73B	2.77B	2.73B
Total Liabilities	5.99B	5.95B	4.92B	5.23B	5.32B
Stockholders Equity	6.74B	5.90B	5.84B	5.30B	5.39B
Cash Flow
Free Cash Flow	1.15B	1.37B	1.47B	1.02B	1.30B
Operating Cash Flow	1.56B	1.75B	1.77B	1.31B	1.49B
Investing Cash Flow	-394.00M	-1.26B	-310.00M	-338.00M	-749.00M
Financing Cash Flow	-715.00M	-752.00M	-930.00M	-1.37B	-696.00M

Agilent Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 137.24
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For A, the sentiment is Neutral. The current price of 137.24 is below the 20-day moving average (MA) of 145.58, below the 50-day MA of 145.06, and above the 200-day MA of 124.15, indicating a neutral trend. The MACD of -2.37 indicates Positive momentum. The RSI at 36.38 is Neutral, neither overbought nor oversold. The STOCH value of 7.99 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for A.

Agilent Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DHR	75 Outperform	$158.82B	46.27	6.84%	0.53%	2.22%	-7.60%
A	73 Outperform	$38.85B	30.03	20.62%	0.72%	6.73%	3.34%
IQV	73 Outperform	$37.58B	30.30	19.55%	―	3.85%	-4.74%
TMO	72 Outperform	$213.34B	32.81	13.14%	0.30%	3.22%	8.26%
WAT	70 Outperform	$22.51B	34.76	32.99%	―	6.90%	3.86%
MTD	64 Neutral	$28.65B	34.98	―	―	4.77%	7.93%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%

Agilent Corporate Events

Agilent Appoints Adam S. Elinoff as CFO

On October 23, 2025, Agilent Technologies announced the appointment of Adam S. Elinoff as the new Chief Financial Officer, effective November 17, 2025. Elinoff, who previously held significant finance roles at Amgen, brings extensive experience in corporate finance, strategy, and transformation. His appointment is expected to bolster Agilent’s financial operations and strategic planning as the company aims to accelerate its Ignite Operating System and enhance value creation for customers and shareholders.